+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Memantine in severe dementia: Results of the 9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)



Memantine in severe dementia: Results of the 9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)



International Journal of Geriatric Psychiatry 14(2): 135-146



Objectives. To assess clinical efficacy and safety of memantine-an uncompetitive N-methyl-D-aspartate (NMDA) antagonist-in moderately severe to severe primary dementia. Materials and methods. Dementia was defined by DSM-III-R criteria and severity was assessed by the Global Deterioration Scale (stages 5-7) and the Mini-Mental State Examination (< 10 points). Primary endpoints were the Clinical Global Impression of Change (CGI-C) rated by the physician, and the Behavioural Rating Scale for Geriatric Patients (BGP), subscore 'care dependence', rated by the nursing staff. Secondary endpoints included the modified D-Scale (Arnold/Ferm). Results. The ITT sample comprised 166 patients and 151 patients were treated per protocol. At 12-week ITT endpoint analysis, 82 received memantine 10 mg per day, 84 placebo. Dementia was in 49% of the Alzheimer type and in 51% of the vascular type (CT, Hachinski score). A positive response in the CGI-C was seen in 73% versus 45% in favour of memantine (stratified Wilcoxon p < 0.001), independent of the etiology of dementia. The results in the BGP subscore 'care dependence' were 3.1 points improvement under memantine and 1.1 points under placebo (p = 0.016). A coincident response of the two independent target variables was observed in 61.3% (memantine) versus 31.6% (placebo). Secondary endpoint analysis of the D-Scale assessing basic ADL functions support the primary results. Regarding the safety profile, no significant differences between treatment groups were observed. Conclusions. The results of this trial support the hypothesis that memantine treatment leads to functional improvement and reduces care dependence in severely demented patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 010972249

Download citation: RISBibTeXText

DOI: 10.1002/(sici)1099-1166(199902)14:2<135::aid-gps906>3.0.co;2-0


Related references

Efficacy and tolerability of memantine in nursing home patients with moderate to severe dementia of the Alzheimers type. European Neuropsychopharmacology 13(Supplement 4): S394, 2003

Combined Memantine And Vitamin D Treatment Provides The Same Cognitive Benefit As Memantine Alone In A Chronically Vitamin D Deficient Double-Transgenic Mouse Model Of Alzheimer'S Disease. Alzheimer's & Dementia 13(7): P269-P270, 2017

The addition of memantine to galantamine increases treatment efficacy in patients with moderate dementia with Lewy bodies. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 118(6. Vyp. 2): 32-36, 2018

Long-term safety and efficacy of memantine treatment in moderate to severe Alzheimer's disease: Results from a three-year trial. Journal of the American Medical Directors Association 8(3), 2007

Memantine Treatment opportunity for severe dementia. European Neuropsychopharmacology 13(Supplement 4): S116-S119, 2003

Questions & answers. We've been told that my wife has multi-infarct dementia and that the new drug memantine may help. How is her condition different from Alzheimer's disease, and what could memantine do for her?. Harvard Mental Health Letter 20(9): 8, 2004

Efficacy and tolerability of memantine in the treatment of dementia. American Journal of Geriatric PharmacoTherapy 2(4): 303-312, 2005

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. International Journal of Clinical Practice 60(1): 110-118, 2006

Clinical and Economic Outcomes of Memantine Used in Moderate or Severe Dementia Patients in China: Results from a Health Economic Model. Value in Health 17(7): A722, 2014

Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 112(1): 35-39, 2012

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opinion on PharmacoTherapy 15(7): 913-925, 2014

Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine Results of a 24-week, open-label extension study in moderate to severe Alzheimers disease. European Journal of Neurology 10(Supplement 1): 160, 2003

Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia. Drugs of Today 52(4): 239-248, 2016

Efficacy of memantine in patients with moderately severe to severe Alzheimer's disease in Japan (dose-finding study). 2007

Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. European Neuropsychopharmacology 10(Supplement 3): S360, 2000